SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$3.20 -0.53%

-$0.02 today

Market cap
$288.28M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 0.89M

Average 0.76M

SABS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

SAB Biotherapeutics, Inc.NASDAQ: SABS

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 79.75M shares rose 758.1% year over year, ahead of the +340.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 48.9% from the prior quarter. Over 3 fiscal years it compounded at +64.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +758.1% holds above the trailing-twelve-month pace of +340.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
79.75M+48.9% QoQ
Last fiscal yearDec 2025
19.31M+108.5% YoY
LTMJun 2026
40.82M+340.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+758.1%——
1 year+108.5%——
3-year CAGR+64.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
19.31M USD
Year-over-year change
+108.5%
4-year CAGR
+45.2%

Weighted Avg Shares vs competitors

How SABS compares with its peers on the latest reported figures

  • SABS's LTM Jun 2026 weighted avg shares of 40.82M shares is the highest of the 5 companies compared; the peer median is 17.58M shares.
  • Its year-over-year change of +340.0% is the highest of 5, against a peer median of +6.3%.
  • Over three fiscal years its annual growth of +64.3% compares with a peer median of +35.7%.
SABS Competitors Peer median
Weighted Avg Shares for SABS and competitors
Company Period LTM YoY 3-year CAGR
SABSSAB Biotherapeutics, Inc.LTM Jun 202640.82M +340.0%+64.3%
ANTXAN2 Therapeutics, Inc.LTM Mar 202631.18M +4.3%+25.4%
BOLDBoundless Bio, Inc.LTM Mar 202622.38M +7.1%+0.2%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 202610.07M +57.7%+46.1%
Peer median (excluding SABS) 17.58M+6.3%+35.7%

Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.88M23.9M2.24M1.32M0
Cost of Revenue1.65M3.29M3.75M4.79M3.08M
Gross Profit59.22M20.61M(1.51M)(3.47M)(3.08M)
Gross Margin97.3%86.2%-67.3%-262.4%—
Research & Development57.18M36.44M16.52M30.16M34.35M
Selling, General & Admin17.09M16.38M23.8M9.28M14.6M
Operating Expenses72.62M49.53M36.57M39.44M45.87M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
EBITDA(15.2M)(15.12M)(38.13M)(28.99M)16.6M
EBITDA Margin-25.0%-63.3%-1703.1%-2192.5%—
Operating Income(13.39M)(28.92M)(38.08M)(42.91M)(48.95M)
Operating Margin-22.0%-121.0%-1700.5%-3244.9%—
Interest Income23.12K71.07K584.97K1.29M1.43M
Interest Expense294.46K301.58K315.28K318.4K240.66K
Other Income / Expenses(3.75M)10.2M(4.12M)8.81M62.23M
Income Before Tax(17.15M)(18.72M)(42.19M)(34.11M)13.27M
Pre-Tax Margin-28.2%-78.3%-1884.5%-2579.0%—
Income Tax Expense025.63K000
Net Income(17.15M)(18.74M)(42.19M)(34.11M)13.27M
Net Margin-28.2%-78.4%-1884.5%-2579.0%—
EPS (Basic)(3.94)(4.31)(7.64)(3.68)0.22
EPS (Diluted)(6.30)(4.31)(7.64)(3.68)(0.79)
Weighted Avg Shares4.35M4.35M5.52M9.26M19.31M
Weighted Avg Shares (Diluted)2.73M4.35M5.52M9.26M61.34M

SAB Biotherapeutics, Inc.

NASDAQ:SABS

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.